Department of Clinical Biochemistry, Rigshospitalet.
Department of Clinical Biochemistry, Bispebjerg Hospital.
Curr Opin Lipidol. 2019 Jun;30(3):212-217. doi: 10.1097/MOL.0000000000000606.
In 2011, the crystal structure of apolipoprotein M (apoM) and its capacity to bind sphingosine-1-phosphate (S1P) was characterized. Since then, a variety of studies has increased our knowledge on apoM biology and functionality. From being an unknown and hardly significant player in overall metabolism, apoM has gained significant interest.
Key discoveries in the last 2 years have indicated that the apoM/S1P complex has important roles in lipid metabolism (affecting triglyceride turnover), inflammation (a marker of severe sepsis and potentially providing anti-inflammatory signaling) and kidney biology (potential to protect against immunoglobulin A nephropathy).
Several studies suggest a potential for apoM/S1P as biomarkers for inflammation, sepsis and nephropathy. Also, a novel chaperone is characterized and could have potential as a drug for treatment in inflammation and nephropathy.
2011 年，载脂蛋白 M（apoM）的晶体结构及其与鞘氨醇-1-磷酸（S1P）结合的能力被阐明。此后，大量研究增加了我们对 apoM 生物学和功能的了解。apoM 从一个在整体代谢中未知且几乎不重要的角色，逐渐受到关注。
过去 2 年的重要发现表明，apoM/S1P 复合物在脂质代谢（影响甘油三酯周转）、炎症（严重败血症的标志物，可能提供抗炎信号）和肾脏生物学（可能预防免疫球蛋白 A 肾病）方面具有重要作用。
几项研究表明，apoM/S1P 可能成为炎症、败血症和肾病的生物标志物。此外，一种新型伴侣蛋白被表征，它可能作为治疗炎症和肾病的药物具有潜力。
